GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors

Part A, B * Primary Objectives * To determine the MTD and RP2D based on safety and tolerability of GM103 as monotherapy. * To evaluate overall safety profile of GM103 as monotherapy. * Secondary Objectives * To assess preliminary anti-tumor efficacy of GM103 at the RP2D, as monotherapy. Part C * Primary Objectives * To determine the MTD and RP2D based on safety and tolerability of GM103 in combination with pembrolizumab. * To evaluate overall safety profile of GM103 in combination with pembrolizumab . * Secondary Objectives * To assess preliminary anti-tumor efficacy of GM103 at the RP2D, in combination with pembrolizumab.